, ,

Can Immunotherapy Improve TB Treatment?

February 1, 2017 at 12:02 am

By Paul Schumacker, PhD, editor, American Journal of Respiratory Cell and Molecular Biology

Follow Dr. Schumacker on Twitter @ATSRedEditor

Immunotherapy Added to Antibiotic Treatment Reduces Relapse of Disease in a Mouse Model of Tuberculosis

Can the addition of immunotherapy to standard antibiotic treatment improve tuberculosis therapy? In a February American Journal of Respiratory Cell and Molecular Biology article, researchers report that in a mouse model of pulmonary tuberculosis, combining three clinically approved immunotherapy agents (all-trans-retinoic acid, 1,25(OH)2-vitamin D3, and α-galactosylceramide) with three antibiotics (isoniazid, rifampicin, and pyrazinamide) resulted in lower mycobacterial loads after five weeks of treatment and significantly reduced relapse after a 13-week course of treatment, compared to antibiotic treatment alone.  The researchers also analyzed cellular changes and cytokine expression and found that mice being treated with immunotherapy as well as antibiotics showed reduced accumulation of immature myeloid cells in the lungs and increased TNF-α protein levels.

February Highlights

miR-34a Inhibits Lung Fibrosis by Inducing Lung Fibroblast Senescence

Lrp5/β-Catenin Signaling Controls Lung Macrophage Differentiation and Inhibits Resolution of Fibrosis

Characterization of N-Acetylglucosamine Biosynthesis in Pneumocystis Species: A New Potential Target for Therapy

IFN-γ Blocks Development of an Asthma Phenotype in Rhinovirus-Infected Baby Mice by Inhibiting Type 2 Innate Lymphoid Cells

Platelet-Specific Chemokines Contribute to the Pathogenesis of Acute Lung Injury


ATS 2016 Full Registration